Brief: Hutchmed (China) Says NDA For Savolitinib Accepted With Priority Review In China
30/12/2025 10:19
Dec 30 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA FOR SAVOLITINIB ACCEPTED WITH PRIORITY REVIEW IN CHINA Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))